17,261 trials
Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants With Molecular Complete Remission at 3 Month Post Transplant — 3 participants
Renal Insufficiency
Primary: AUC (0-t) of Plasma Metformin — 5362; 10411; 8705; 11788 ng*h/mL — p=0.0011
Dysphagia
Primary: Change in Swallow Response Time for 5 cc Thin Liquid Swallows — 2; 2; 4; 3 participants
Pulmonary Hypertension
Primary: Change in Peak Total Pulmonary Resistance Index (TPRI) During Exercise From Baseline to Week 12 — 15.096; 13.954; 15.441; 14.608 mmHg/(L/min/m^2) — p=0.95
Kidney Cancer · Melanoma (Skin) · Metastatic Cancer
Primary: Central Nervous System (CNS) Response Rate by RECIST Criteria — 3; 2 participants
Lung Cancer
Primary: Objective Response Rate (CR + PR by RECIST) Paclitaxel, Pemetrexed, and Bevacizumab in Patients With Advanced Non-Small Lung Cancer Who Have Received no Prior Treatment…
Hypercholesterolemia · Hyperlipoproteinemia Type II
Primary: Number of Participants Who Incurred at Least One Treatment Emergent Event — 33; 10 participants
Glaucoma · Ocular Hypertension
Primary: Mean IOP at Week 6 — 20.2; 18.7; 19.9; 19.3 mmHg
Lymphoma
Primary: Complete Response Rate — 65 percentage of evaluable participants
Pancreatic Cancer
Primary: Progression-free Survival — 5.7 months
Nicotine Dependence
Primary: Mean of the Average Nicotine Binding % at Scan 1 and Scan 2 — 54.9; 49.1 percentage of average nicotine binding — p=<0.05
Hodgkin Lymphoma
Primary: Overall Response Rate — 20.0 percentage of participants
Central Nervous System Tumor, Pediatric
Primary: 2-yr Overall Survival — 0.70 probability
Arteriovenous Fistula
Primary: Percentage of Participants With Arteriovenous Fistula (AVF) Maturation by Week 12 Visit Based on Hemodialysis or Color-flow Doppler Ultrasound (CDUS) And Vascular Access…
Tooth Loss
Primary: Bone Mineral Density of Bone Core — .79; .78 mg/mm^3